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Abstract
Goals—To define the influence of nonalcoholic fatty liver disease (NAFLD) and its associated
comorbidities on liver transplant outcomes.
Background—NAFLD cirrhosis is an increasing indication for transplant. The transplant
outcomes of NAFLD patients with metabolic syndrome comorbidities remain unclear.
Study—We examined a single center, retrospective cohort between 2004 and 2007 to determine
transplant mortality for NAFLD and non-NAFLD patients accounting for the possible independent
effects of diabetes, hypertension, obesity, and hyperlipidemia. The primary outcomes were 30-day,
1-year, and 3-year all-cause mortality. Cox proportional hazard ratios were determined controlling
for various recipient and donor covariates.
Results—In our study, of 118 liver transplants, 18% were performed for NAFLD cirrhosis.
Adjusted hazard ratios for death for NAFLD compared with non-NAFLD patients at 30 days, 1
year, and 3 years were 8.96 (1.06, 75.8), 1.49 (0.38, 5.81), and 1.05 (0.29, 3.78), respectively.
Compared with nondiabetic patients, diabetic patients had hazard ratios at 30 days, 1 year, and 3
years of 2.02 (0.31, 12.9), 2.82 (0.94, 8.47), 3.58 (1.32, 9.71), respectively. Obesity, hypertension,
and hyperlipidemia did not have a significant impact on posttransplant mortality.
Conclusions—We conclude that NAFLD increases 30-day transplant mortality whereas
diabetes increases 3-year mortality. Future work should determine the strategies to decrease
perioperative mortality among NAFLD patients and ways to improve long-term transplant survival
among diabetics.
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The increasing number of nonalcoholic fatty liver disease (NAFLD) patients with liver
failure may alter the practice and outcomes of liver transplant over the next 20 years during
which NAFLD may become the leading indication for liver transplant.1 There are limited
published data to document the postoperative course of patients transplanted for NAFLD.
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Malik et al,2 suggest an early increase in mortality among NAFLD patients, but longer term
survival was similar to patients undergoing transplant for other indications. Other data and
opinions on the impact of NAFLD are mixed.3,4 Historically, many cases of NAFLD
cirrhosis may have been labeled as cryptogenic cirrhosis, and survival data for this entity are
mixed as well.5,6
Comorbidities such as obesity, diabetes, and cardiovascular disease that are associated with
NAFLD likely confer independent risk of poor outcome after transplant and confuse the
issue of increased posttransplant mortality attributed to NAFLD. Some studies have
demonstrated a detrimental impact of diabetes and coronary artery disease (CAD) on liver
transplant outcomes, while the risk imposed by hypertension is equivocal.7,8 Morbid obesity
[body mass index (BMI) ≥ 35] is associated with increased operative risk.9 However, the
impact of these risks on posttransplant NAFLD patients is unknown.
We sought to determine whether NAFLD conveyed an increased risk of posttransplant
mortality independent of the risk factors commonly associated with NAFLD patients,
specifically obesity, diabetes, hypertension, and hyperlipidemia. We also examined graft
loss between NAFLD and non-NAFLD patients, as we wondered whether NAFLD patients
may have more atherosclerotic disease in the hepatic or celiac artery putting them at higher
risk for thrombosis or stenosis.
METHODS
We performed a single center, retrospective cohort study. Consecutive adult (age ≥ 18) liver
transplants performed at the University of North Carolina (UNC) Hospitals between March
27, 2004 and December 31, 2007 were identified via UNC’s transplant database, TransChart
(TransChart, LLC, Dublin, OH). Retransplants were excluded. Further data were obtained
via the United Network of Organ Sharing database and from electronic patient medical
records where appropriate. Data collection was performed after approval from the UNC
Institutional Review Board.
NAFLD was defined as biopsy proven NAFLD/nonalcoholic steatohepatitis (NASH) or
cryptogenic cirrhosis plus at least 2 components of the metabolic syndrome (BMI >30,
hypertension, diabetes, or hyperlipidemia; Fig. 1). Hypertension was defined as systolic
blood pressure >140mm Hg or diastolic blood pressure >90mm Hg or taking an
antihypertensive medication (excluding a non-selective β blocker). Diabetes was defined as
random blood sugar >200 or using oral diabetic medication or insulin injections.
Hyperlipidemia was defined as total cholesterol greater than 200, LDL cholesterol greater
than 160 or taking a cholesterol lowering medication. CAD was defined as a documented
history of CAD or a left heart catheterization with at least 1 lesion obstructing >50% of an
epicardial blood vessel. Obesity was defined as BMI>30. BMI was treated as both a
continuous variable and a categorical variable. All definitions were applied before
transplant. Data on the presence of hepatocellular carcinoma (HCC) were collected as well.
Bivariate analysis was used to compare patients with and without NAFLD and patients with
and without diabetes, hypertension, hyperlipidemia, and obesity. χ2 tests were used for
categorical variables and Student T test was used for continuous variables where
appropriate.
Kaplan-Meier survival analysis was performed censoring patients at the time of death, time
of graft failure, or end of study period to determine 30-day, 1-year, and 3-year patient and
graft survivals. Multivariate analysis with Cox proportional hazards modeling was used to
calculate hazard ratios adjusted for potential confounding factors. These included recipient
race, sex, age, comorbidities, MELD score, warm and cold ischemia time, donor age,
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donation after cardiac death, and donor sex, after excluding interaction terms and colinearity
among variables. Donor risk indices were determined as described by Feng et al.10 The main
outcome was all-cause mortality. Results of the bivariate analyses were used to select
candidate variables for the model. The model was reduced using a backwards elimination
strategy, a priori retaining variables that were significant at a P<0.10 level or those thought
to be clinically important. Patients with missing data were excluded from bivariate and
multivariate analyses. All statistical analyses were performed with Stata version 9
(Statacorp, College Station, TX).
RESULTS
Study Population Characteristics
After excluding retransplants and patients under the age of 18, 118 transplants met the
criteria for inclusion during the study time frame (Table 1). The mean age at transplant was
53±8.3; 70% of the population was male and 74% was white. NAFLD was the indication for
21 (18%) transplants. Among the patients without NAFLD, 25 (21%) had hepatitis C
(HCV), another 16 (14%) had cirrhosis due to HCV and alcohol, 15 (13%) had cirrhosis due
to alcohol alone, 8 (7%) were transplanted for hepatitis B, and 33 (28%) were transplanted
for other indications including primary biliary cirrhosis, primary sclerosing cholangitis, and
autoimmune hepatitis. The mean MELD score at transplant was 23.6±6.2. Thirty-three
patients (28%) had diabetes. The majority of the donor population (61%) was female; the
mean donor age was 36.2±15.3. The mean Donor Risk Index (DRI) was 1.333±0.309. Mean
cold ischemia time was 420±117 minutes. Mean and median times to discharge after
transplant were 23 and 13 days, respectively. These times were not significantly different
between NAFLD and non-NAFLD patients (mean 20.9 vs. 23.5, respectively, P=0.669;
median 13 for both, P=0.792). Posttransplant survival was 95% at 30 days, 87% at 1 year,
and 82% at 3 years.
NAFLD and Effect on Survival
Bivariate analysis of the NAFLD and non-NAFLD populations is shown in Table 2;
NAFLD patients were significantly older (57.9 y vs. 52.1 y, P=0.003), and had worse
pretransplant renal function (serum creatinine 1.9 vs. 1.4, P=0.022). As would be expected
by our definition of NAFLD cases, diabetes (62% vs. 21%, P<0.001) and hyperlipidemia
(33% vs. 8%, P=0.002) were more prevalent compared with non-NAFLD patients.
Hypertension and BMI were also more prevalent in the NAFLD cohort but the difference
did not reach statistical significance. There were no differences in the donor or operative
characteristics between these populations. Mean DRI for the NAFLD and non-NAFLD
groups were 1.28 and 1.35, respectively, P=0.42.
The Kaplan-Meier survival curve for NAFLD and non-NAFLD patients is shown in Figure
2. Thirty-day survival for the NAFLD population was significantly worse compared with the
same for non-NAFLD population (81% vs. 97%, P=0.001). Of the 4 NAFLD patients dying
within 30 days, 2 died of hepatic artery thrombosis, 1 died of cardiac complications, and 1
died of multisystem organ failure. Of the 2 non-NAFLD patient dying within 30 days, 1 died
of sepsis and 1 died of cardiac complications. One-year and 3-year survival for NAFLD
patients was worse as well (76% vs. 90%, P=0.063 at 1 year, 76% vs. 84%, P=0.235 at 3
years). Graft survival followed a similar trend (Table 2). When survival among the non-
NAFLD cohort was evaluated by etiology of disease, patients transplanted for hepatitis B
had 100% 30-day survival, 88% 1-year survival, and 70% 3-year survival. Patients with
HCV had 96%, 92%, and 87% 30-day, 1-year, and 3-year survival, respectively. HCV plus
alcohol survival had 100%, 94%, and 80%; alcohol alone had 100%, 87%, and 87%; other
indications for transplant had 97%, 87%, and 83% survival at 30 days, 1 year, and 3 years,
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respectively. There were no differences in causes of death between NAFLD and non-
NAFLD patients.
Unadjusted Cox proportional hazard modeling showed NAFLD patients had a 9.59
(P=0.009), 2.66 (P=0.074), and 1.84 (P=0.243) hazard of death at 30 days, 1 year, and 3
years, respectively compared with non-NAFLD patients. A fully adjusted model was
created, adjusting for age, race, sex, diabetes, hypertension, hyperlipidemia, CAD, BMI,
MELD score, HCC, and the components of DRI. This model was then reduced to adjust for
diabetes, cold ischemia time, MELD score, and donor cause of death. The final, reduced
model showed NAFLD patients had 8.96 (P=0.04), 1.49 (P=0.56), and 1.05 (P=0.94) hazard
of death at 30 days, 1 year, and 3 years, respectively for NAFLD patients compared with
non-NAFLD patients. The final, reduced model was unchanged from the fully adjusted
model (Table 4). Using the individual components of MELD did not significantly change
the model.
Diabetes and Effect on Survival
Bivariate analysis of the diabetic and nondiabetic populations is shown in Table 3 and
demonstrated that the diabetic patients were significantly older (56.5 y vs. 51.8 y, P=0.005),
more likely to have hypertension (46% vs. 22%, P=0.013), and more likely to have HCC
(42% vs. 20%, P=0.003). There were no differences in the donor or operative characteristics
between these populations. Mean DRI for the diabetic and nondiabetic groups were 1.27 and
1.35, respectively, P=0.21.
The Kaplan-Meier survival curve for diabetic and nondiabetic patients is shown in Figure 3.
Thirty-day and 1-year survival for the diabetic population was worse compared with the
nondiabetic population (90% vs. 97%, P=0.232 at 30 d and 78% vs. 90%, P=0.077 at 1 y).
Three-year survival for diabetic patients was significantly worse (63% vs. 89%, P=0.006).
Graft survival followed a similar trend (Table 3). There were no significant differences in
causes of death between diabetic and nondiabetic patients, although there were 2 deaths due
to sepsis in the diabetic group versus none in the nondiabetic group.
Unadjusted Cox proportional hazard modeling showed diabetic patients had 2.56 (P=0.25),
2.43 (P=0.087), and 3.28 (P=0.010) hazard of death at 30 days, 1 year, and 3 years
compared with nondiabetic patients. A fully adjusted model was created, adjusting for age,
race, sex, NAFLD, HCV, hypertension, hyperlipidemia, CAD, BMI, MELD score, HCC,
and the components of the DRI. This model was then reduced to adjust for cold ischemia
time, MELD score, and donor cause of death. The final, reduced model showed diabetic
patients had 2.02 (P=0.46), 2.82 (P=0.06), and 3.58 (P=0.01) hazard of death at 30 days, 1
year, and 3 years compared with nondiabetic patients. The final, reduced model was
unchanged from the fully adjusted model (Table 4).
Hypertension, Hyperlipidemia, Obesity, CAD, and Effect on Survival
Within the study population, 29% had hypertension, 13% had hyperlipidemia, and 42% had
a BMI of 30 or greater. These risk factors did not have a significant impact on posttransplant
mortality. Only 5 patients were transplanted with documented CAD. All these 5 patients had
at least 1 epicardial coronary vessel with a ≥50% lesion; however, none received a
percutaneous coronary intervention or coronary artery bypass grafting before transplant. Cox
modeling demonstrated increased hazard for death in patients with CAD at 30 days, 1 year,
and 3 years, but the trend did not meet statistical significance.
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NAFLD cirrhosis is a rapidly increasing indication for transplant. The posttransplant
outcomes of NAFLD patients with metabolic syndrome comorbidities remain unclear. We
sought to compare posttransplant mortality between NAFLD and non-NAFLD patients, and
to determine the independent effects of diabetes, hypertension, obesity, and hyperlipidemia
on posttransplant survival. We also examined graft survival between groups hypothesizing
that NAFLD patients may have more atherosclerotic disease of the hepatic and celiac
arteries putting them at increased risk of thrombosis or stenosis.
The main findings from this study are that NAFLD confers an independent risk of early
mortality in the first 30 days after liver transplant. Diabetes mellitus is an independent risk
factor for longer term posttransplant mortality. Hypertension, hyperlipidemia, and a BMI>30
do not independently contribute to posttransplant mortality. CAD likely confers an
independent risk for posttransplant mortality, even in our highly selected population;
however, the number of patients with CAD was too small to draw a firm conclusion.
The reasons for an increased 30-day mortality associated with NAFLD patients are difficult
to discern as the absolute number of deaths in our NALFD cohort was small. None of the
deaths within the study were attributed to intraoperative technical problems. There was 1
intraoperative cardiac arrest in the non-NAFLD cohort. The causes of death within the first
30 days in the NAFLD cohort included cardiac complications, hepatic artery thrombosis,
and multisystem organ failure. Each of these etiologies may be linked to unrecognized
atherosclerotic disease, either in the coronary arteries or in the peripheral circulation; a
plausible explanation as NAFLD has been linked both independently and as an
epiphenomenon to atherosclerotic disease11,12 Our medical chart review was unable to
define cardiac disease as the only factor in this 30-day window of increased mortality risk,
however. Likewise, interaction between NAFLD comorbidities (diabetes, obesity,
hypertension, and hyperlipidemia) did not explain the increased mortality risk. Therefore,
the reason for NAFLD to be associated with early posttransplant mortality, independent of
typical comorbidities considered, remains unclear.
Only 1 other study has examined posttransplant outcomes specifically in NAFLD patients
(2). Malik et al found a tendency for increased 30-day mortality and identified a subgroup of
NAFLD patients that had increased overall mortality. Most of the deaths were within the
first 50 days posttransplant similar to our overall cohort of NAFLD patients. They used a
case-control design, histologic diagnosis of NAFLD only, and did not provide a multivariate
analysis. Compared with PBC/PSC and HCV controls, NAFLD patients received livers from
significantly older donors by 5.2 and 6.9 years, respectively. This difference could have
contributed to the earlier deaths. Our study defined NAFLD based on broader clinical
parameters and had the advantage of a cohort design with multivariate analysis. No
differences in donor age or DRI were seen between the cohorts in our study.
The NAFLD cohort in our study consisted of patients with biopsy proven NASH and
patients with cryptogenic cirrhosis plus at least 2 risk factors of the metabolic syndrome.
Previous studies have documented high rates of diabetes and obesity among patients with
cryptogenic cirrhosis and NASH.13,14 Other studies have concluded that many patients
previously labeled as having cryptogenic cirrhosis probably had NAFLD cirrhosis based on
clinical parameters.15 Therefore, we chose to use a clinical diagnosis of NAFLD cirrhosis in
addition to a strict histologic one. In practice, histologic diagnosis of NAFD cirrhosis is
difficult due to loss of fat as fibrosis progresses. We felt that a more inclusive NAFLD
diagnosis would be more useful and relevant to clinical practice.
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The classification of NAFLD patients was verified by chart review of all included patients;
those found to have other diagnoses (sarcoidosis n=1, and methotrexate toxicity n=2) were
excluded. None of the patients in our NAFLD cohort had serologic, genetic, or biochemical
markers consistent with genetic disorders of the liver, viral hepatitis, or autoimmune
hepatitis. None were thought to have had surreptitious alcohol use after extensive evaluation
by out transplant psychologists who are employed solely by our transplant division and
devote nearly 100% of their time to pretransplant evaluations. All explants are reviewed
jointly by the liver histopathologists and clinical team in conference to check for potential
missed diagnoses. Any such missed diagnoses are then immediately corrected in our
transplant database. Although protocol biopsies were not performed after transplant, 9 of the
21 NAFLD patients underwent a liver biopsy for the indication of suspected rejection. All of
these biopsies occurred between 3 months and 1 year posttransplant. Of the 9, 3 (33%)
showed recurrence of NASH.
Diabetic patients had lower survival at each time point after liver transplant coming close to
statistical significance at 1 year (HR 2.82, P=0.06) and reaching significance at 3 years
(3.58, P=0.01). A nearly identical trend was seen for graft failure (Table 4). These poorer
outcomes for diabetic patients have been previously reported.7,8,16 However, 2 of the prior
studies did not account for any donor variables, whereas the third accounted for donor age
and cold ischemia time only.7 All 3 studies were done in the pre- MELD era. Our study
suggests that the effect of diabetes on posttransplant survival is independent of donor
characteristics and persists in the MELD era.
Overall, there was no significant difference among causes of death between patients with
and without diabetes; however, 2 patients with diabetes died of infectious complications
versus none of the patients without diabetes. The persistently lower survival of patients with
diabetes over time is not surprising considering the adverse effects of immunosuppressive
regimens on the metabolic syndrome.17 Moreover, the presence of the metabolic syndrome
has been independently linked to posttransplant fibrosis progression among HCV patients at
more than 1-year posttransplant.18 This effect may hold true for non-HCV patients as well.
In summary, NAFLD is associated with early (30 d) posttransplant mortality while diabetes
is an independent risk for longer term (3 y) mortality. Together, pretransplant diabetes and
NAFLD have the potential to significantly erode posttransplant outcomes over the next
decade as the proportion of NAFLD patients with advanced liver disease increases, thus
adding support to Forman’s labeling the metabolic syndrome as the “the elephant in the
room.”19 Future work must determine precise reasons and preventive measures for early
mortality among NAFLD patients and later deaths in diabetics.
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Selection of the NAFLD cohort. Risk factors for a clinical diagnosis of NAFLD defined as
hypertension, hyperlipidemia, diabetes, and obesity. NAFLD indicates nonalcoholic fatty
liver disease.
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Kaplan-Meier survival curves for patients with and without NAFLD. Unadjusted P values
for log-rank Kaplan-Meier curve censored at day 30 (P = 0.001), day 365 (P = 0.063), and
day 1095 (P = 0.235). NAFLD indicates nonalcoholic fatty liver disease.
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Kaplan-Meier survival curves for patients with and without diabetes. Unadjusted P values
for log-rank Kaplan-Meier curve censored at day 30 (P=0.232), day 365 (P=0.076), and day
1095 (P=0.006).
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TABLE 1
Characteristics of the Study Population
Recipient characteristics
 Transplants, total 118
 Mean age at transplant 53.1±8.3
  n (%) male 83 (70)
  n (%) white 87 (74)
 Indications for transplant, n (%)
  NAFLD 21 (18)
  Non-NAFLD 97 (82)
 MELD at transplant 23.6±6.2
  n with diabetes (%) 33 (28)
   n with hypertension (%) 34 (29)
  n with hyperlipidemia (%) 15 (13)
  n with coronary artery disease (%) 5 (4)
  n with hepatocellular carcinoma (%) 31 (26)
  Mean serum sodium 136±5.3
  Mean creatinine 1.47±1.0
  Mean body mass index 28.8±4.6
Donor characteristics
 Male donors, n (%) 43 (39)
 Donor age 36.2±15.3
 Donor type, n (%)
  Deceased donor 107 (91)
  DCD 10 (9)
 Donor cause of death, n (%)
  Anoxia 9 (9)
  CVA 41 (38)
  Trauma 56 (52)
 Donor Risk Index 1.333±0.309
Operative characteristics
 Warm ischemia time, min 40.5±11.2
 Cold ischemia time, min 420±117
 Retransplants required, n (%) 13 (11)
Survival
 Overall graft survival (%)
  30 d 92.4
  1 y 82.1
  3 y 74.3
 Overall patient survival (%)
  30 d 94.9
  1 y 87.1
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  3 y 82.3
NAFLD indicates nonalcoholic fatty liver disease.
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TABLE 2
Bivariate Analysis of Patients With and Without Nonalcoholic Fatty Liver Disease
NAFLD (n=21) Non-NAFLD (n=97) P
Recipient characteristics
 Mean age at transplant, years 57.9±6.2 52.1±8.3 0.003
 n (%) male 12 (57) 71 (73) 0.144
 n (%) white 17 (81) 70 (72) 0.407
 MELD 23.4±6.8 23.6±6.15 0.881
 n with diabetes (%) 13 (62) 20 (21) <0.001
 n with hypertension (%) 9 (43) 25 (26) 0.117
 n with hyperlipidemia (%) 7 (33) 8 (8) 0.002
 n with coronary artery disease (%) 1 (5) 4 (4) 0.895
 n with hepatocellular carcinoma (%) 4 (19) 27 (28) 0.407
 Mean body mass index 30.2±4.2 28.6±4.7 0.156
 Mean serum sodium 135±4 136±6 0.366
 Mean creatinine 1.9±1.1 1.4±1.0 0.022
Donor characteristics
 Male donors, n (%) 9 (47) 34 (38) 0.437
 Donor age 35.4±15.3 36.4±15.4 0.798
 Donor type
  Deceased donor 19 (90) 88 (92)
  DCD 2 (10) 8 (8) 0.709
 Donor cause of death, n (%)
  Anoxia 0 (0) 9 (11)
  CVA 5 (26) 36 (41)
  Trauma 14 (74) 42 (47) 0.122
 Donor Risk Index 1.280±0.396 1.345±0.288 0.417
Operative characteristics
 Warm ischemia time, min 39.4±7.4 40.8±11.9 0.602
 Cold ischemia time, min 414±111 422±119 0.774
 Required retransplant, n (%) 3 (14) 10 (10) 0.598
 Days to discharge posttransplant 20.9±18.6 23.5±24 0.669
Survival
 Graft survival, %
  30 d 80.9 94.9 0.0266
  1 y 76.2 83.4 0.3285
  3 y 76.2 73.2 0.7761
 Patient survival, %
  30 d 80.9 97.0 0.0014
  1 y 76.2 89.5 0.0632
  3 y 76.2 83.5 0.2352
 Patient cause of death, n (%)
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NAFLD (n=21) Non-NAFLD (n=97) P
  Graft failure/1 liver disease* 0 (0) 2 (14)
  Infection/sepsis 1 (20) 1 (7)
  Cardiac 1 (20) 3 (21)
  Biliary complication 0 (0) 3 (21) 0.577
  Other 3 (60)* 5 (36)†
*
Hepatic artery thrombosis ×2, multisystem organ failure.
†
Hepatocellular carcinoma, neuroendocrine tumor, graft versus host disease, trauma, multisystem organ failure.
NAFLD indicates nonalcoholic fatty liver disease.













Barritt et al. Page 15
TABLE 3
Bivariate Analysis of Patients With and Without Diabetes
Diabetes (n=33) No Diabetes (n=85) P
Recipient characteristics
 Mean age at transplant 56.5±8.8 51.8±5.5 0.005
 n (%) male 23 (69.7) 60 (70.6) 0.92
 n (%) white 28 (84.9) 59 (69.4) 0.09
 MELD 22.3±5.3 24.1±6.5 0.16
 n with hypertension (%) 15 (45.5) 19 (22.3) 0.013
 n with hyperlipidemia (%) 7 (21.2) 8 (9.4) 0.08
 n with coronary artery disease (%) 1 (3.0) 4 (4.7) 0.69
 n with hepatocellular carcinoma (%) 14 (42.4) 17 (20) 0.013
 Mean body mass index 30.9±4.2 28.1±4.6 0.0036
 Mean serum sodium 136±4.9 136±5.5 0.91
 Mean creatinine 1.4±0.8 1.5±1.1 0.65
Donor characteristics
 Male donors, n (%) 10 (33.3) 33 (41.8) 0.42
 Donor age 36.8±14.2 36.0±15.8 0.81
Donor type
  Deceased donor 29 (89) 78 (92) 0.27
  DCD 3 (10) 7 (8)
 Donor cause of death, n (%)
  Anoxia 2 (7) 7 (9) 0.45
  CVA 8 (28) 33 (42)
  Trauma 19 (64) 37 (47)
 Donor Risk Index 1.27±0.35 1.35±0.29 0.21
Operative characteristics
 Warm ischemia time, min 39.7±6.1 40.9±12.6 0.60
 Cold ischemia time, min 404±125 426±115 0.37
 Required retransplant, n (%) 2 (6.1) 11 (12.9) 0.28
Survival
 Graft survival, %
  30 d 90.9 92.9 0.7183
  1 y 78.2 83.5 0.5335
  3 y 56.3 80.4 0.0632
 Patient survival, %
  30 d 90.1 96.5 0.2319
  1 y 78.2 90.4 0.0765
  3 y 63.3 88.9 0.0063
 Patient cause of death, n (%)
  Graft failure/1 liver disease* 2 (20) 0 (0)
  Infection/sepsis 2 (20) 0 (0)
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Diabetes (n=33) No Diabetes (n=85) P
Cardiac 1 (10) 3 (33) 0.26
 Biliary complication 1 (10) 2 (22)
 Other 4 (40)* 4 (44)†
*
Hepatic artery thrombosis, multisystem organ failure, trauma, neuroendocrine tumor.
†
Hepatic artery thrombosis, hepatocellular carcinoma, graft versus host disease, multisystem organ failure.
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TABLE 4
Adjusted Hazard Ratios for Graft Failure and Death
Hazard Ratio (95% Confidence Interval)
Graft Failure Death
Risk of graft failure and death, reduced model*
 NAFLD
  30 d 8.96 (1.06, 75.8) 8.96 (1.06, 75.8)
  1 y 1.49 (0.38, 5.81) 1.49 (0.38, 5.81)
  3 y 0.94 (0.27, 3.27) 1.05 (0.29, 3.78)
 Diabetes
  30 d 2.02 (0.31, 12.9) 2.02 (0.31, 12.9)
  1 y 2.82 (0.94, 8.47) 2.82 (0.94, 8.47)
  3 y 2.51 (0.99, 6.37) 3.58 (1.32, 9.71)
Diabetes reduced model adjusted for cold ischemia time, donor cause of death, and MELD score.
*
The NAFLD reduced model was adjusted for diabetes, cold ischemia time, donor cause of death, and MELD score.
NAFLD indicates nonalcoholic fatty liver disease.
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